Department of Radiology
Found 5 results
Filters: Keyword is Radiation Dosage  [Clear All Filters]
2023
Dawd JE, Ozsahin DUzun, Ozsahin I.  2023.  DEVELOPING DIAGNOSTIC REFERENCE LEVELS FOR CT EXAMINATIONS IN ADDIS ABABA, ETHIOPIA.. Radiat Prot Dosimetry. 199(3):ncac263235245-245.
Mauguen A, Grewal RK, Augensen F, Abusamra M, Mahajan S, Jayaprakasam VSudar, Osborne J, Haque S, Z Y Wong B, Ghossein RA et al..  2023.  The use of single-timepoint images to link administered radioiodine activity (MBq) to a prescribed lesion radiation-absorbed dose (cGy): a regression-based prediction interval tool for the management of well-differentiated thyroid cancer patients.. Eur J Nucl Med Mol Imaging. 50(10):2971-2983.
2016
Melsaether AN, Raad RA, Pujara AC, Ponzo FD, Pysarenko KM, Jhaveri K, Babb JS, Sigmund EE, Kim SG, Moy LA.  2016.  Comparison of Whole-Body (18)F FDG PET/MR Imaging and Whole-Body (18)F FDG PET/CT in Terms of Lesion Detection and Radiation Dose in Patients with Breast Cancer.. Radiology. 281(1):193-202.
Pandit-Taskar N, O'Donoghue JA, Ruan S, Lyashchenko SK, Carrasquillo JA, Heller G, Martinez DF, Cheal SM, Lewis JS, Fleisher M et al..  2016.  First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake.. J Nucl Med. 57(12):1858-1864.
2014
Pandit-Taskar N, O'Donoghue JA, Beylergil V, Lyashchenko S, Ruan S, Solomon SB, Durack JC, Carrasquillo JA, Lefkowitz RA, Gönen M et al..  2014.  ⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer.. Eur J Nucl Med Mol Imaging. 41(11):2093-105.